



AMENDMENTS TO THE SPECIFICATIONIN THE SPECIFICATION:

Please amend the paragraph at page 12, line 1 to line 10 as follows:

Based on ingredients of Table 1 below, an aqueous drug solution was prepared and filtered through a membrane filter (type: GS, pore diameter: 0.22 $\mu$ m prepared by Millipore Ltd.). The filtrate (1mL) was filled into a glass 3mL-ampoule. Each ampoule was sterilized in vapor at 100°C for 15 min to obtain a liquid preparation.

Drug: Camptothecin derivative described in Example 84 of Jp-10-72467A as represented by the following formula:





wherein CM means "carboxymethylated".

Please amend the paragraph at page 15, line 14 to page 16,  
line 12 as follows:

The amount (%) of free active camptothecin in each sample was calculated as 100% of the amount of free active camptothecin compound produced by adding 10 times amount of 6N hydrochloric acid to the sample solution preserved in a refrigerator and then heating at 100°C for 4 hours.

HPLC conditions:

- Column: Inertsil ODS (prepared by GL Science Inc.)
- Mobile phase: 35mM formic acid-ammonium formate buffer (pH3)/acetonitrile=80/20 (flow: 1.0mL/min.)
- Column temperature: 40°C
- Detection: Fluorophotometer (Ex=360, Em=420nm)
- Active camptothecin compound:



wherein Ra is hydrogen atom, Gly-, Gly-Gly- or Gly-Gly-Gly-.